Unconventional Uses of Scleral Lenses - Summary - MDSpire

Unconventional Uses of Scleral Lenses

This course discusses the diverse applications of scleral lenses beyond vision correction, including piggyback scleral lenses, oblate designs for keratoconus, scleral lenses for ptosis, drug delivery, prism correction, low vision, and optic decentration for fitting.

  • By

  • Daddi Fadel, DOptom

  • Melissa Barnett, OD, FAAO, FSLS

  • July 1, 2025

  • 20 min

Share

Objective:

To explore diverse applications of scleral lenses, particularly in addressing ocular challenges such as keratoconus and high myopia.

Key Findings:
  • Scleral lenses (SLs) can address various ocular challenges, including keratoconus and high myopia, by improving centration and reducing visual disturbances.
  • Oblate lens designs enhance centration and minimize visual disturbances associated with high-minus lenses.
  • Customizing the front optic zone of scleral lenses significantly enhances visual performance.
Interpretation:

Expanding the use of scleral lenses is crucial for maximizing patient outcomes and providing effective alternatives when conventional methods fall short.

Limitations:
  • The article lacks specific clinical trial data to substantiate all claims, which may limit the reliability of the findings.
  • Potential biases from faculty remuneration could influence the recommendations made.
Conclusion:

Scleral lenses present innovative solutions for complex ocular conditions, and understanding their full potential is essential for eyecare professionals.

Original Source(s)

Unconventional Uses of Scleral Lenses

  • by Daddi Fadel, DOptom, Melissa Barnett, OD, FAAO, FSLS

  • July 1, 2025

Related Content

CSO Meeting 2026 Highlights Convergence of Innovation and Clinical Practice

More than 300 professionals gathered for three days of innovation, education, and collaboration, highlighting the latest advances in ophthalmic technology and clinical practice

  • May 12, 2026

  • 2 min
Theialife Appoints New CEO

Ahead of phase 3 myopia push, late clinical-stage biopharmaceutical company takes on Thomas Ruggia as Chief Executive Officer

  • May 18, 2026

  • 2 min
Is This the New Norm?: <br>Is the End of Specialty CL Labs the New Norm?</br>